Sionna therapeutics reports first quarter 2025 financial results

Phase 1 dosing completed for nbd1 stabilizers sion-719 & sion-451; both compounds continue to be generally well tolerated phase 1 topline data anticipated this quarter on track to initiate phase 2a proof-of-concept trial and at least one dual combination mad trial in the second half of 2025; topline data for both anticipated in mid-2026 strong cash position following completed upsized ipo, with approximately $354.7 million in cash and cash equivalents, expected to fund operations into 2028 waltham, mass., may 12, 2025 (globe newswire) -- sionna therapeutics, inc. (nasdaq: sion), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (cf) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (cftr) protein, today reported financial results for the quarter ended march 31, 2025, and provided a business update.
SION Ratings Summary
SION Quant Ranking